Treatment of hepatitis B virus replication by ganciclovir in kidney transplant patients

Garnier, J. L.; Chossegros, P.; Daoud, S.; Chevallier, Philippe; Dubernard, Jean Michel; Trépo, C; Touraine, J. L.

doi:10.1016/s0041-1345(96)00146-7

Cited by 8 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ganciclovir was able to decrease the level of HBV DNA in transplant patients (Garnier et al, 1997), but universal relapse occurs after withdrawal. Lamivudine therapy has been shown, at least in the short term, to be efficient in liver-transplant (Grellier et al, 1996;Kruger et al, 1996) as well as in renal-transplant patients (Jung et al, 1998;Rostaing et al, 1997).…”

Section: Discussionmentioning

confidence: 96%

Effects of long-term lamivudine therapy in renal-transplant patients

Kamar

Sandres-Sauné²,

Ribes

et al. 2004

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Effects of long-term lamivudine therapy in renal-transplant patients

Kamar

Sandres-Sauné²,

Ribes

et al. 2004

Journal of Clinical Virology

View full text Add to dashboard Cite

“…Recent investigations [80, 81]used ganciclovir in the treatment of chronic hepatitis B among kidney transplant recipients, and a strong reduction of HBV DNA levels after therapy was seen. A 5-month therapy with foscarnet, a pyrophosphate analogue, has been able to eliminate HB s Ag and HBV DNA in a RT patient with HB s Ag-related liver disease [82].…”

Section: Treatment Of Hbv-related Liver Disease In Rt Recipientsmentioning

confidence: 99%

Hepatitis B Virus and Renal Transplantation

Fabrizi

Martin

Ponticelli

2002

Nephron

View full text Add to dashboard Cite

“…The well-known antiherpesvirus drugs ACV and GCV are guanosine analogs with acyclic sugars. GCV reportedly inhibits DHBV replication in primary duck hepatocytes with an EC 50 of 2.5 M (3), while ACV has only modest activity against HBV in vitro (19): both compounds have been used against HBV in animal models (7,42) and humans (12,32). ddG is active against HBV in cultured cells, with a reported EC 50 of 2.3 M (19), and its TP form selectively inhibits DHBV Pol (16).…”

Section: Compoundsmentioning

confidence: 99%

In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir

Seifer

Hamatake

Colonno

et al. 1998

Antimicrob Agents Chemother

185

View full text Add to dashboard Cite

The guanosine analogs BMS-200475 and lobucavir have previously been shown to effectively suppress propagation of the human hepatitis B virus (HBV) and woodchuck hepatitis virus (WHV) in 2.2.15 liver cells and in the woodchuck animal model system, respectively. This repression was presumed to occur via inhibition of the viral polymerase (Pol) by the triphosphate (TP) forms of BMS-200475 and lobucavir which are both produced in mammalian cells. To determine the exact mode of action, BMS-200475–TP and lobucavir-TP, along with several other guanosine analog-TPs and lamivudine-TP were tested against the HBV, WHV, and duck hepatitis B virus (DHBV) polymerases in vitro. Estimates of the 50% inhibitory concentrations revealed that BMS-200475–TP and lobucavir-TP inhibited HBV, WHV, and DHBV Pol comparably and were superior to the other nucleoside-TPs tested. More importantly, both analogs blocked the three distinct phases of hepadnaviral replication: priming, reverse transcription, and DNA-dependent DNA synthesis. These data suggest that the modest potency of lobucavir in 2.2.15 cells may be the result of poor phosphorylation in vivo. Kinetic studies revealed that BMS-200475–TP and lobucavir-TP competitively inhibit HBV Pol and WHV Pol with respect to the natural dGTP substrate and that both drugs appear to bind to Pol with very high affinities. Endogenous sequencing reactions conducted in replicative HBV nucleocapsids suggested that BMS-200475–TP and lobucavir-TP are nonobligate chain terminators that stall Pol at sites that are distinct yet characteristically two to three residues downstream from dG incorporation sites.

show abstract

Treatment of hepatitis B virus replication by ganciclovir in kidney transplant patients

Cited by 8 publications

References 0 publications

Effects of long-term lamivudine therapy in renal-transplant patients

Effects of long-term lamivudine therapy in renal-transplant patients

Hepatitis B Virus and Renal Transplantation

In Vitro Inhibition of Hepadnavirus Polymerases by the Triphosphates of BMS-200475 and Lobucavir

Contact Info

Product

Resources

About